|Articles|December 2, 2002

Test

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX

ByNicholas Jacobus

November 7th 2025

Image Credit: Adobe Stock Images/Tada Images. The latest selections for the CNPV include therapies for obesity, cancer, sickle cell disease, and drug-resistant tuberculosis.

FDA Continues to Expand National Priority Voucher Program

ByDavy James

November 7th 2025

FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma

ByNicholas Jacobus

November 7th 2025

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

ByThani Jambulingam, PhD

November 7th 2025

Deb Nevins is the Chief Marketing & Strategy Officer at POCN Group. POCN Group, an IQVIA business, is the life-sciences engagement division of POCN.

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

ByDeb Nevins

November 7th 2025

Test

Newsletter

Related Content

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX

FDA Continues to Expand National Priority Voucher Program

FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

Trending on PharmExec

FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma

Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX

FDA Continues to Expand National Priority Voucher Program

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore